Anwarul Haq, MD, MRCP(UK) Neurologist BUMC · 2018-04-24 · Anwarul Haq, MD, MRCP(UK) Neurologist...

Anwarul Haq, MD, MRCP(UK) Neurologist

BUMC

It is a relentlessly progressive disease of the Motor System Commonly known as Lou Gehrig’s Disease Called Motor Neuron Disease in Britain A relatively uncommon disorder Incidence 1.8/100,000 population Prevalence of 2-7/100, 000 population

The ‘iron horse’

History First described by Charcot

in 1869

The science of ALS, however, remained largely descriptive

In 1990 World Federation of Neurology met in El Escorial, Spain and published the diagnostic criteria for ALS

The EE criteria was considered too restrictive and was relaxed in 1998

The first breakthrough came in 1991

Teepu Siddique et al, at Northwestern University Chicago, identified the 1st genetic mutation causing ALS in some families

Superoxide dismutase gene on chromosome 21

This led to the development of animal models of ALS and the ability to rationally develop and test drugs for ALS

In 1994 Riluzole was reported to prolong survival in ALS (Bensimon et al)

Multiple other genetic mutations have since been identified in familial ALS

How is the Nervous System organized?

What is in the motor system?

Lower motor neuron (LMN) signs: Weakness, muscle wasting, hyporeflexia, muscle cramps,

fasciculations, weakness

Upper motor neuron (UMN) signs: Spasticity, hyper-reflexia, weakness

Epidemiology Incidence 1.8/100,000 population Prevalence of 2-7/100, 000 population In the United States, about 7000 new cases of ALS are

diagnosed each year 90% of cases are sporadic 10% are familial (FALS); most commonly autosomal

dominant Male:Female – 1.4: 1 Average age at onset is ~ 60 years Can start in teens or >75yrs

Glutamate excitotoxicity Free radical injury Neurofilament and Microtubule dysfunction Ubiquilin2 (which is involved in recycling damaged and

misformed proteins in key nerve cells). In people with ALS, ubiquilin2 does not do this effectively, leading to an accumulation of the damaged proteins and ubiquilin2 in critical nerve cells in the spinal cord and brain (Nature 2011)

Patients present with a combination of upper and lower motor neuron signs

Clinical patterns at presentation Progressive bulbar palsy Progressive Muscular Atrophy Primary lateral sclerosis ALS (UMN + LMN)

These patterns then progressively merge to develop full blown ALS picture (UMN + LMN)

Tongue atrophy

Leg wasting

Hand atrophy

El Escorial criteria

Prognosis Mean survival from onset is 23-43 months 5-yr. survival rate of 22% 10-yr. survival rate of 9.4% Poor prognostic factors:

Age >65 yr Rapid disease progression Dyspnea at onset Rapid decline in pulmonary function

Can any tests help in diagnosis? There is no blood marker of S-ALS Diagnosis depends on the clinical picture EMG can be helpful by showing characteristic findings:

fibrillations, fasciculations, reinnervation motor units Blood tests and imaging can help rule out other diseases

Multidisciplinary Approach

Neurologist Clinical/research nurse Dietician Speech/swallowing

therapist Family/caregivers Psychologists

Physical therapist Occupational therapist Social worker GI physician Support organizations Homehealth/hospice Pulmonologist

Phramacotherapy - specific Riluzole was approved in 1996 It acts as an antiglutamate agent Median prolongation of survival of 2 months

Phramacotherapy - symptomatic Fatigue: pyridostigmine, SSRIs, Amantadine Spasticity: Baclofen, Tizanidine Cramps: Quinine, Clonazepam Psedobulbar affect: Dextromethorphan/Quinidine, SSRIs, Depressions: SSRIs, TCAs,

Speech and Communication Speech therapists to be involved early Introduce energy conserving skills Introduce non-verbal techniques Introduce assistive and augmentative devices

Respiratory care Goals and limitations of any intervention should be

discussed in detail Non-invasive Positive Pressure Ventilation is used Generally offered when FVC <50%, patient is short of

breath or when symptomatic hypercapnia occurs

Thank you